Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer

Phase 2CadonilimabPositive

AI Analysis

Summary

Akeso, Inc. announced a Phase II clinical trial collaboration with Memorial Sloan Kettering Cancer Center to evaluate cadonilimab, a PD-1/CTLA-4 combination immunotherapy, for perioperative treatment of gastric cancer in the United States.

Clinical Trial Data

Phase

Phase II

Importance:5/10

Sentiment:

0.50

Phase_2_TrialImmunotherapyGastric_CancerPD-1_CTLA-4Clinical_CollaborationUS_Study

Related Companies

$9926.HK

Read the original article

Published by PR Newswire Clinical Trials on July 14, 2026 8:18 AM

Read Original